CLASSIF1 Classification


Pretherapeutic Identification of High Risk AML Patients


fig.1: Database      >fig.2

- Eight patient and clinical chemistry parameters, one overall survival (OS) indicator for clinical outcome, 25 cytogenetic abnormalities and 36 flow cytometric immunophenotype parameters at diagnosis were available for classification. One color indirect (FITC-F(ab')2 fragments (L2) immunophenotypes were used throughout the study for reasons of compatibility with the early determinations of the multicenter trial.



© 2024 G.Valet
1965-2006: Max-Planck-Institut für Biochemie, Am Klopferspitz 18a, D-82152 Martinsried, Germany
Last Update: Mar.31,2003